/
Oncology
B-Cell Acute Lymphoblastic Leukemia
31
Pipeline Programs↗
38
Active Trials↗
24
Companies Involved↗
B-cell acute lymphoblastic leukemia is a moderately active landscape with 31 programs across 24 companies. The most active players are Novartis, Excyte Biopharma Ltd, Gilead. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical11
Phase 18
Phase 29
Approved
No programs
Analysis
Modality Breakdown
23programs
Small molecule1357%
Cell therapy522%
Monoclonal antibody417%
Antibody–drug conjugate14%
Modality classified for 94% of 31 pipeline programs.
Analysis
Trial Status
73
clinical trials
Recruiting26 · 36%
Unknown status16 · 22%
Completed8 · 11%
Active, not recruiting7 · 10%
Terminated7 · 10%
Not yet recruiting5 · 7%
Other4 · 5%
Clinical Trials
Trial Activity
73 trials
A Phase 2 Randomized Trial of Caloric Restriction and Activity to Reduce Chemoresistance in B-cell Acute Lymphoblastic Leukemia
Recruiting·—·Phase 2·NCT05082519·240 enrolled
Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia
Recruiting·—·Phase 1·NCT06447987·24 enrolled
Page 1 of 5
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)